Clinical Observation of Sacubitril and Valsartan in the Treatment of Heart Failure with Preserved Ejection Fraction
Objective To investigate the effect of sacubitril and valsartan on holter electrocardiogram indicators and expression levels of serum angiotensin Ⅱ(Ang Ⅱ)and galactin-3(Gal-3)proteins in patients with heart failure with preserved ejection fraction(HFpEF).Methods A total of 110 patients with HFpEF admitted to the Eighth People's Hospital of Hefei from February 2020 to February 2023 were selected and randomly divided into the observation group and the control group,with 55 cases in each group.The patients in the observation group took sacubitril and valsartan orally,while the patients in the control group took perindopril.Both groups were treated for 6 months.Results The total effective rate in the observation group was 92.73%,which was significantly higher than 72.73% in the control group(P<0.05).After treatment,the Minnesota Heart failure Quality of Life Questionnaire(MLHFQ)score,left ventricular end-diastolic diameter(LVEDd),left ventricular end-systolic diameter(LVESd),and the expression levels of serum Ang Ⅱ and Gal-3 protein in the two groups significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).The 6-minute walking test(6MWT)distance in the two groups significantly prolonged(P<0.05),and that in the observation group was significantly longer than that in the control group(P<0.05).The left ventricular ejection fraction(LVEF),the ratio of peak early mitral velocity to peak late mitral velocity(E/A)of anterior mitral valve diastolic blood flow,and the mean standard deviation of R-R interval per 5 min segment within 24 h(SDANN),the standard deviation of all normal to normal R-R intervals(SDNN),and the composition ratio of R-R interval difference between adjacent normal cardiac cycles≥50 ms(PNN50)were significantly higher than those before treatment(P<0.05),and those in the observation group were significantly higher than those in the control group(P<0.05).Conclusion Sacubitril and valsartan has good clinical efficacy in the treatment of patients with HFpEF,which can improve the heart function and exercise endurance of patients.The mechanism may be through reducing the expression levels of serum Ang Ⅱ and Gal-3 proteins,and the formation of interstitial fibrosis in the heart,so as to reverse myocardial remodeling.
sacubitril and valsartanheart failure with preserved ejection fractionangiotensin Ⅱgalactose lectin-3
国家科技期刊平台
NSTL
万方数据
